Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

• Published in: Cancer chemotherapy and pharmacology Vol. 79; no. 2; pp. 315 - 326
• Main Authors: Infante, Jeffrey R., Patnaik, Amita, Verschraegen, Claire F., Olszanski, Anthony J., Shaheen, Montaser, Burris, Howard A., Tolcher, Anthony W., Papadopoulos, Kyriakos P., Beeram, Muralidhar, Hynes, Scott M., Leohr, Jennifer, Lin, Aimee Bence, Li, Lily Q., McGlothlin, Anna, Farrington, Daphne L., Westin, Eric H., Cohen, Roger B.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2017; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Cancer Research; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor - administration & dosage; Humans; Kinesin - antagonists & inhibitors; Male; Maximum Tolerated Dose; Medicine; Medicine & Public Health; Middle Aged; Neoplasms - drug therapy; Oncology; Original Article; Pharmacology/Toxicology; Polyethylene Glycols; Recombinant Proteins - administration & dosage; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Thiadiazoles - administration & dosage; Thiadiazoles - adverse effects; Thiadiazoles - pharmacokinetics; Kinesin spindle protein (KSP); Eg5; Phase 1; KSP inhibitor; Antimitotic
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-016-3205-5

Purpose This first-in-human report examined the recommended Phase 2 dose and schedule of litronesib, a selective allosteric kinesin Eg5 inhibitor. Methods Two concurrent dose-escalation studies investigated litronesib across the dose range of 0.125–16 mg/m 2 /day, evaluating the following schedules of administration on a 21-day cycle: Days 1, 2, 3; Days 1, 5, 9; Days 1, 8; Days 1, 5; or Days 1, 4, with or without pegfilgrastim. Best overall response was defined per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). Pharmacokinetic (PK) evaluations were performed. Exploratory PK/pharmacodynamic analyses investigated the relationship between litronesib plasma exposure and changes in phosphohistone H3 (pHH3) levels. Results One hundred and seventeen patients with advanced malignancies were enrolled. Neutropenia was the primary dose-limiting toxicity. Prophylactic pegfilgrastim reduced neutropenia frequency and severity, allowing administration of higher litronesib doses, but increases in the incidences of mucositis and stomatitis were observed. Among 86 response-evaluable patients, 2 patients (2%) achieved partial response, both on the Days 1, 2, 3 regimen (5 and 6 mg/m 2 /day with pegfilgrastim), and 17 patients (20%) maintained stable disease for ≥6 cycles. Dose-dependent increases in litronesib plasma exposure were observed, with minor intra- and inter-cycle accumulation, along with exposure-dependent increases in pHH3 expression in tumor and skin biopsies. Conclusions On the basis of the results of these studies, two regimens were selected for Phase 2 exploration: 6 mg/m 2 /day on Days 1, 2, 3 plus pegfilgrastim and 8 mg/m 2 /day on Days 1, 5, 9 plus pegfilgrastim, both on a 21-day cycle.